Therapy-related myeloid neoplasms (t-MNs) are severe long-term consequences of cytotoxic treatments for a primary, often, malignant disorder. So far, the majority of patients eligible for transplantation have undergone myeloablative allo haematopoietic SCT (HSCT) as a potentially curative treatment, but it has been associated with high transplantation-related mortality (TRM) rates. In this retrospective study, we analysed the outcome of patients with t-MNs undergoing HSCT with reducedintensity conditioning (RIC). Of 55 patients, seen at a single centre over a 10-year period, 17 underwent RIC HSCT with related or unrelated donors. The estimated overall survival was 53% at 1 year and 47% at 3 years, and disease-free survival was 47% at 1 year. At 1 year, the cumulative incidence of relapse and TRM were 24% and 30%, respectively. Of five patients with active primary neoplasms who underwent transplantation, two are alive beyond 1 year and show CR of both t-MNs and the primary malignancy. These data indicate that RIC HSCT is an encouraging approach for patients with t-MNs. The issue of primary malignancies not being in remission at the time of transplantation should be explored in further studies.
Introduction
Therapy-related myeloid neoplasms (t-MNs) are severe long-term consequences of cytotoxic treatments for solid tumours, haematological malignancies and autoimmune disorders. 1 Patients who require long-term immunosuppressive medication after solid organ transplantation also have a significantly increased risk of t-MNs. 2 According to the WHO classification, t-MNs constitute a separate disease entity comprising therapy-related (t) myelodysplastic syndrome (t-MDS), t-AML and myelodysplastic/ myeloproliferative neoplasms (t-MDS/MPN). 3 t-MNs account for about 10% of all cases of MDS and AML 4, 5 and their incidence is expected to rise due to a steady increase of long-term cancer survivors. The prognosis for patients with t-MNs depends on several host and leukaemia-related factors, including age and performance status as well as the genetic profile of leukaemic cells. As compared with de novo AML, favourable cytogenetic and molecular risk factors-t(15;17), t(8;21), inv (16) or NMP1 mutations-are less prevalent in t-AML cases. 6 However, even when stratified for genetic risk, t-AML remains an independent adverse prognostic factor as has been demonstrated in prospective AML trials. 7, 8 Allo haematopoietic SCT (HSCT) is recommended as a potentially curative treatment option for patients with t-MDS and t-AML with intermediate and adverse genetic risk factors. 9 This procedure is, however, associated with high transplantation-related mortality (TRM) rates, as has been demonstrated in both paediatric and adult patients with t-MNs. [10] [11] [12] [13] [14] [15] Recently, two retrospective registry-based reports by the European Group for Blood and Marrow Transplantation 16 and the Centre for International Bone Marrow Transplantation Research 17 reported on risk factors that significantly influenced the outcome of patients with t-MNs. Both groups were able to show that the survival of patients with t-MNs was between 4 and 62% depending on risk group and comparable to de novo counterparts.
Allo HSCT with reduced-intensity conditioning (RIC) was introduced almost two decades ago to attenuate toxicity and make this procedure available to older people and those with comorbidities, [18] [19] [20] [21] [22] [23] nonetheless, it is only rarely reported in t-MN cohorts. Here, we present results obtained with RIC HSCT in patients with t-MNs at a single centre. Those with persistent primary neoplasms were also included and we were able to demonstrate a graft-vs-primary malignancy effect in a subset of these individuals.
Patients and methods

Patients
Between January 2000 and December 2009, 55 patients with t-MNs were seen in the Division of Haematology, Medical University of Graz, Graz, Austria, which is a tertiary referral centre for a population of 1.5 million people. This study focused on patients with t-MNs who received an allo HSCT. Diagnostic criteria for t-MNs were applied according to published guidelines. 3, 24 Staging and restaging procedures were performed immediately before HSCT and 4 weeks, 3 and 12 months thereafter, and included-depending on the primary disease-PET and CT scans, bone scintigraphy and BM examination.
Of these 55 patients, 17 proceeded to RIC HSCT. Reasons for ineligibility for HSCT were age above 70 years (n ¼ 22), poor performance status (n ¼ 15) and refusal (n ¼ 1). The transplant cohort consisted of 4 men and 13 women with a median age of 50 years (range, 28-66 years). Primary disorders were solid tumours (n ¼ 8) and haematologic malignancies (n ¼ 9), primary cytotoxic treatments were chemotherapy (n ¼ 5), radiotherapy (n ¼ 3) and combined modality treatment (n ¼ 9) as well as auto SCT (n ¼ 3). The median latency period between initial cytotoxic treatment and diagnosis of t-MNs was 43 months (range, 10-153 months). Four patients had t-MDS, twelve t-AML and one t-MDS/MPN. Cytogenetic analysis of BM aspirates obtained at t-MN diagnosis revealed clonal aberrations in 14/17 patients (82%) including isolated chromosome 7 abnormalities (n ¼ 3), isolated chromosome 3 abnormalities (n ¼ 1), a complex karyotype (n ¼ 4) and other clonal aberrations (n ¼ 6). All patients received granulocyte CSF mobilised, unmanipulated PBMC grafts. Graft-vs-host disease (GvHD) prophylaxis consisted of CYA (started on day À1 before HSCT at 1.5 mg/kg twice daily, aimed at therapeutic trough levels of 200-250 ng/mL and tapered after 4 months if no GvHD developed) and mycophenolate mofetil (started in the afternoon on day 0 with 15 mg/kg and from day þ 1, twice daily until day þ 35, tapered until day þ 42). In unrelated donor HSCTs, anti-thymocyte globulin (Fresenius Biotech, Munich, Germany) was added at 5 mg/kg/day from day À5 to À2 (total dose 20 mg/kg). Infectious disease prophylaxis was administered in accordance with current guidelines of the 'Infectious Diseases Working Party of the German Society of Haematology and Oncology' (https://www. dgho-infektionen.de). Donor chimaerism studies were routinely performed on day þ 28 and at 1 year after HSCT. When no full donor chimaerism was achieved by day þ 28 or graft failure was suspected, the analysis was repeated at regular intervals. 25 DNA was extracted from both peripheral blood granulocytes and sorted CD3 þ T-lymphocytes, and STR sequences were analysed with a commercially available kit (AmpFlSTR Profiler Plus KIT, Applied Biosystems, Warrington, UK). Complete donor chimaerism was defined as more than 99% donor cells. Assessment of acute and chronic GvHD was performed in accordance with published guidelines. 26, 27 Written informed consent was obtained from all patients before HSCT and data were reported to the European Group for Blood and Marrow Transplantation.
Statistical analysis
Patient characteristics were reported descriptively. Overall survival (OS) was defined as the time from HSCT to death from any cause. Disease-free survival (DFS) was defined as the time from HSCT to disease relapse or death from any cause, whichever occurred first. Patients alive or lost to follow-up were censored at the time they were last seen alive. TRM was defined as death unrelated to either t-MNs or primary malignancies. The probabilities of OS and DFS were estimated using Kaplan-Meier curves whereas TRM and relapse were calculated using cumulative incidence estimates and taking into account the competing risk structure. 28 All statistical analyses were performed with SPSS version 18.0 (SPSS, Chicago, IL, USA). The study was approved by the institutional review board of the Medical University of Graz, Graz, Austria, in accordance with the principles of the Declaration of Helsinki.
Results
Transplantation outcomes
The median PBSC dose infused was 5.1 Â 10 6 CD34 þ cells per kg recipient weight (range 2.7-10.5). Median time to neutrophil engraftment was 14 days (range 11-21) and platelet engraftment 11 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Three patients died before day þ 28 post HSCT, and chimaerism analysis was, therefore, available for 14/17 individuals who showed a full donor chimaerism. All evaluable patients achieved a CR of their t-MNs by day þ 28. Relapse of t-MNs occurred in four patients between 3 and 5 months post HSCT. Acute and chronic GvHD was observed in five patients each (Table 1) . Of those eight patients with sustained CR of their neoplasms, five experienced chronic GvHD.
The median follow-up for the cohort of surviving patients undergoing RIC HSCT for t-MNs was 31 months (range, 14-93). The median OS was 13 months, the estimated OS at 1 year was 53% (95% confidence interval (CI) 29-77) and at 3 years was 47% (95% CI, 23-70). The median DFS was 5 months and the estimated DFS at 1 year was 47% (95% CI, 23-71) (Figure 1) . At 1 year, the cumulative incidence of relapse and TMR were 24% and 30%, respectively.
Transplantation of patients with t-MNs and active primary malignancies Among this cohort, five patients underwent RIC HSCT with a primary malignancy in PR (Table 1) . Whereas one each died of multiorgan failure, acute GvHD and leukaemia progression post HSCT, two individuals showed persistent CR of both t-MNs and primary malignancy. Moderate. 'Latency' refers to the time between initiation of cytotoxic therapy for the primary malignancy and diagnosis of t-MNs.
The grey shading indicates that these five patients underwent HSCT with a primary malignancy in partial remission. 
Discussion
Treatment of patients with t-MNs is a challenging task and the outcome of these individuals is still dismal. Only a proportion of patients with t-MNs proceed to HSCT despite the fact that adverse prognostic parameters are overrepresented in this group as compared with patients with de novo MDS and AML. In our cohort, 38/55 (69%) patients were ineligible for HSCT, mainly because of age and poor performance status, and these 'real world data' are consistent with a prior report. 29 Allo HSCT is the only potentially curative treatment for most patients with t-MNs. The vast majority of reports have focused on the use of myeloablative HSCT. In a study by the Seattle group, 5-year DFS was between 8 and 30% depending on the conditioning regimen and the 5-year cumulative incidence of non-relapse mortality between 42 and 58%. 11 The French Society of Bone Marrow Transplantation reported 2-year EFS and TRM rates of 28% and 49%, respectively. 12 However, the use of RIC HSCT has rarely been reported in those with t-MNs. Chang et al. 13 described the outcome of HSCT in 257 patients with secondary MDS/AML following previous cytotoxic therapy or an antecedent haematologic disorder. Of those, 26 were transplanted with non-myeloablative conditioning. The 5-year relapse-free survival was 29% for the entire group and 23% for those conditioned with fludarabine/low-dose TBI. In a retrospective analysis by the Centre for International Bone Marrow Transplantation Research, Litzow et al. presented data on a cohort of patients with t-MNs. RIC HSCT was applied in 23% of them but was not associated with reduced TRM; this might be because a high proportion of patients in this group had received auto SCT for their primary malignancy. Although the cohort of patients with t-MNs described in our analysis is small, the results of RIC HSCT with an estimated 3-year-survival of 47% are encouraging, especially, when taking into account the high percentage of individuals with adverse-risk European Group for Blood and Marrow Transplantation scores. These data may therefore stimulate the prospective evaluation of RIC HSCT in patients with t-MNs.
The issue of active primary neoplasms at the time of HSCT for patients with t-MNs has not been addressed before. Here we show that CR of both primary malignancy and t-MNs occurred in two patients following RIC HSCT.
Notably, chronic GvHD developed in both patients. A graft-vs-malignancy effect following allo HSCT is well known and has been described primarily in patients with haematological neoplasms including myeloma and CLL. [30] [31] [32] [33] [34] However, it has also been observed in patients with solid tumours. [35] [36] [37] Similar to haematologic malignancies, the disease status at the time of HSCT and the occurrence of chronic GvHD are strong predictive outcome parameters. Patients with t-MNs and a primary malignancy not in CR are, however, ineligible for allo HSCT in many centres, donor registries and clinical studies. Thus, our results may stimulate the exploration of this issue in further studies.
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